These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 24671340)
1. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. van den Brink W; Sørensen P; Torup L; Mann K; Gual A; J Psychopharmacol; 2014 Aug; 28(8):733-44. PubMed ID: 24671340 [TBL] [Abstract][Full Text] [Related]
2. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Gual A; He Y; Torup L; van den Brink W; Mann K; Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264 [TBL] [Abstract][Full Text] [Related]
3. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Mann K; Bladström A; Torup L; Gual A; van den Brink W Biol Psychiatry; 2013 Apr; 73(8):706-13. PubMed ID: 23237314 [TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. van den Brink W; Strang J; Gual A; Sørensen P; Jensen TJ; Mann K Expert Opin Drug Saf; 2015 Apr; 14(4):495-504. PubMed ID: 25652768 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. van den Brink W; Aubin HJ; Bladström A; Torup L; Gual A; Mann K Alcohol Alcohol; 2013; 48(5):570-8. PubMed ID: 23873853 [TBL] [Abstract][Full Text] [Related]
7. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401 [TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence. Higuchi S; Takahashi M; Murai Y; Tsuneyoshi K; Nakamura I; Meulien D; Miyata H Psychiatry Clin Neurosci; 2020 Aug; 74(8):431-438. PubMed ID: 32359104 [TBL] [Abstract][Full Text] [Related]
9. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis. Soyka M; Friede M; Schnitker J Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589 [TBL] [Abstract][Full Text] [Related]
10. Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial. Miyata H; Takahashi M; Murai Y; Tsuneyoshi K; Hayashi T; Meulien D; Sørensen P; Higuchi S Psychiatry Clin Neurosci; 2019 Nov; 73(11):697-706. PubMed ID: 31298784 [TBL] [Abstract][Full Text] [Related]
11. The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients. François C; Rahhali N; Chalem Y; Sørensen P; Luquiens A; Aubin HJ PLoS One; 2015; 10(6):e0129289. PubMed ID: 26053024 [TBL] [Abstract][Full Text] [Related]
12. Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results. Barrio P; Ortega L; Guardia J; Roncero C; Yuguero L; Gual A Clin Drug Investig; 2018 Feb; 38(2):147-155. PubMed ID: 29080208 [TBL] [Abstract][Full Text] [Related]
13. Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials. Palpacuer C; Laviolle B; Boussageon R; Reymann JM; Bellissant E; Naudet F PLoS Med; 2015 Dec; 12(12):e1001924. PubMed ID: 26694529 [TBL] [Abstract][Full Text] [Related]
14. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485 [TBL] [Abstract][Full Text] [Related]
15. Nalmefene: a review of its use in the treatment of alcohol dependence. Keating GM CNS Drugs; 2013 Sep; 27(9):761-72. PubMed ID: 23949908 [TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients. Aubin HJ; Reimer J; Nutt DJ; Bladström A; Torup L; François C; Chick J Eur Addict Res; 2015; 21(3):160-168. PubMed ID: 25832297 [TBL] [Abstract][Full Text] [Related]
17. Nalmefene and its use in alcohol dependence. Gual A; Bruguera P; López-Pelayo H Drugs Today (Barc); 2014 May; 50(5):347-55. PubMed ID: 24918835 [TBL] [Abstract][Full Text] [Related]
18. Can alcohol dependent patients adhere to an 'as-needed' medication regimen? Sinclair J; Chick J; Sørensen P; Kiefer F; Batel P; Gual A Eur Addict Res; 2014; 20(5):209-17. PubMed ID: 24557083 [TBL] [Abstract][Full Text] [Related]
19. Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis. Mueller S; Luderer M; Zhang D; Meulien D; Brach BS; Schou MB Alcohol Alcohol; 2020 Feb; 55(1):63-70. PubMed ID: 31713583 [TBL] [Abstract][Full Text] [Related]
20. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]